Clinical Trial Update: Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a quadruple combination therapy (Trastuzumab Rezetecan, Pertuzumab, Iparomlimab, and Tuvonralimab) for biliary tract cancer.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Pertuzumab (pertuzumab)
• Trastuzumab Rezetecan
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Biliary Tract Cancer (BTC), First-line Therapy | Phase 2 | Status: NOT_YET_RECRUITING